Sažetak
Background: Pathogenic *BRCA1/2* variant carriers require effective surveillance for high-grade serous ovarian cancer (HGSOC), a malignancy characterized by late-stage detection and poor prognosis. Current monitoring with CA-125 and transvaginal ultrasound lacks sensitivity for early-stage disease.
Objective: To develop and validate a multi-analyte serum panel for the preclinical detection of HGSOC in *BRCA1/2* carriers.
Methods: In a prospective, multicenter longitudinal cohort, we enrolled 450 women with pathogenic *BRCA1/2* variants. Serial serum samples were collected every 6 months. The study included 45 incident HGSOC cases and 405 matched controls. Levels of CA-125, HE4, miR-200a, and IL-6 were quantified using immunoassays and RT-qPCR. A composite risk score was derived using logistic regression, and diagnostic performance was evaluated using ROC curve analysis, sensitivity, specificity, and lead-time assessment.
Results: All four biomarkers were significantly elevated in pre-diagnostic samples from HGSOC cases (p<0.001). The combined panel achieved an AUC of 0.95 (95% CI: 0.92-0.98), significantly outperforming individual markers (CA-125 AUC=0.86; HE4 AUC=0.82; miR-200a AUC=0.88; IL-6 AUC=0.70; DeLong's test p<0.01). At a 90% specificity threshold, the panel's sensitivity was 88%, compared to 68% for CA-125 alone. The panel detected HGSOC a median of 12 months (IQR: 8-16) prior to clinical diagnosis, with a lead-time sensitivity of 72% at 18 months pre-diagnosis.
Conclusion: The integrated serum panel of CA-125, HE4, miR-200a, and IL-6 demonstrates exceptional diagnostic accuracy for the preclinical detection of HGSOC in BRCA carriers. This panel represents a transformative potential for structured surveillance programs, enabling earlier intervention and personalized risk management.
Ključne reči
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.